Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Metformin, the first-line drug for type II diabetes, has recently been considered an anticancer agent. However, the molecular target and underlying mechanism of metformin’s anti-cancer effects remain largely unclear. Herein, we report that metformin treatment increases the sensitivity of hepatocarci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yinghui, Lu, Hui, Sun, Linchong, Chen, Xin, Wei, Haoran, Suo, Caixia, Feng, Junru, Yuan, Mengqiu, Shen, Shengqi, Jia, Weidong, Wang, Ying, Zhang, Huafeng, Li, Zijun, Zhong, Xiuying, Gao, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487431/
https://www.ncbi.nlm.nih.gov/pubmed/34601503
http://dx.doi.org/10.1038/s41419-021-04199-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487431/
https://www.ncbi.nlm.nih.gov/pubmed/34601503
http://dx.doi.org/10.1038/s41419-021-04199-1

Ejemplares similares